Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on July 28, 2019. The filing discloses the entry into a Material Definitive Agreement with Lonza Biologics Tuas Pte. Ltd. for the commercial production of narsoplimab (OMS721), the company's lead human monoclonal antibody targeting MASP-2.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of a new commercial manufacturing agreement.
Material Changes and Agreement Terms
- Agreement Purpose: Lonza will manufacture commercial quantities of narsoplimab following regulatory marketing approvals, replacing a previous agreement focused on development services and clinical supplies.
- Pricing and Obligations: Omeros will purchase batches based on forecasts. Pricing varies by the total number of batches in a manufacturing campaign. Omeros is obligated to purchase a minimum number of batches annually starting from the first commercial sale in the U.S. or EU.
- Term: The initial term expires five years after the first commercial sale, with an option for automatic renewal for an additional four years unless non-renewal notice is given three years prior.
- Termination: The agreement may be terminated if regulatory approval is not obtained, if the drug is withdrawn from both markets, for material breach, or due to bankruptcy/insolvency.
Outlook, Risks, and Management Commentary
Omeros is preparing a biologics license application for the U.S. FDA and a marketing authorization application for the European Medicines Agency for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The company also maintains ongoing Phase 3 clinical programs for narsoplimab in immunoglobulin A (IgA) nephropathy and atypical hemolytic uremic syndrome (aHUS). The filing notes that certain competitively harmful information regarding the agreement has been redacted.
Investor Verification Checklist
- Verify the specific minimum batch purchase obligations and associated costs once the first commercial sale occurs.
- Monitor the status of the biologics license application for HSCT-TMA and Phase 3 results for IgA nephropathy and aHUS.
- Review the full Master Services Agreement (filed as an exhibit to the Q3 2019 Form 10-Q) for detailed pricing tiers and cancellation fees.
- Assess the impact of the agreement on future cash burn rates and capital requirements for commercialization.